Beyond the Classic Triad: An Unusual Phenomenology of Parkinsonism in a Patient with Superficial Siderosis (SS)
Objective: To highlight the phenomenology in a complex case of superficial siderosis (SS) presenting with hearing loss, ataxia, and parkinsonism Background: SS is a rare…Risk factors for central nervous system side effects of amantadine
Objective: The purpose of this study was to investigate the threshold blood level of amantadine and risk factors for central nervous system (CNS) side effects…Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors
Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…A Case of Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson’s Disease
Objective: We present a case with a paradoxical gait response to levodopa in Parkin gene-related early-onset Parkinson's Disease. Background: Parkin (PRKN) mutations are the predominant…Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment
Objective: To advance translational research by revealing detailed relationships between neural circuit activity and behavioural symptoms in preclinical models Background: Conventional preclinical tests for CNS…Delayed movement disorders after usage of desomorphine-“crocodile”. Clinical case.
Objective: To study the clinical and neuroimaging features of a patient with a long-term use (more than 10 years) of desomorphine in the anamnesis. Background:…Craniofacial Myoclonus: A Disabling Complication of Amantadine Therapy
Objective: We describe a patient who developed amantadine-induced craniofacial myoclonus with speech impairment. Few cases have been reported [1], thus we offer an additional case…Clinical profile of early-onset Parkinson’s disease
Objective: Describe motor and non-motor symptoms, complications and treatment in patients with early-onset Parkinson's disease (EOPD) Background: PD usually affecting people over age 60, clinically…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…
- 1
- 2
- 3
- …
- 5
- Next Page »